Diabetes, Vol 44, Issue 11 1290-1295, Copyright © 1995 by American Diabetes Association

ARTICLES

Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase

MA Myers, DU Rabin and MJ Rowley
Centre for Molecular Biology and Medicine, Monash University, Victoria, Australia.

The presence of serum islet cell cytoplasmic antibodies (ICAs) is a standard autoimmune marker for insulin-dependent diabetes mellitus (IDDM). The antigenic molecule(s) responsible for ICA has not been identified, although antibodies to the 65-kDa isoform of glutamic acid decarboxylase (GAD65) do contribute. We tested 129 IDDM sera for antibodies to ICA512 (anti-ICA512), antibodies to GAD (anti-GAD), and ICAs; we tested for inhibition of ICAs with purified recombinant ICA512 and sheep brain GAD; and we tested for immunofluorescence reactivity on COS7 cells transfected with cDNA clones encoding ICA512 and GAD65. The results were that anti-ICA512 antibodies contribute to ICA reactivity and that these, in combination with anti-GAD antibodies, account for most ICA reactivity in IDDM. Anti-ICA512 antibodies were present at a frequency of 51% in 61 patients with early-onset IDDM (age of onset < or = 20 years) of short duration (< or = 1 month) but only in 9% of 68 patients with an onset age of > 20 years and/or a disease duration of > 1 month. The frequency of anti-GAD antibodies in these sera was similar irrespective of duration or age of onset. Anti-ICA512 and anti-GAD antibodies were demonstrable by indirect immunofluorescence on transfected COS7 cells, and ICA could be inhibited using either recombinant ICA512 or purified brain GAD. We conclude that anti-ICA512 and anti-GAD antibodies contribute to ICA reactivity and that anti-ICA512 antibodies account for the increased frequency of ICA reactivity in early-onset IDDM of short duration.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Diabetes Care, January 1, 2003; 26(90001): s5 - 20. [Full Text] [PDF]

				W. E. Winter, N. Harris, and D. Schatz Immunological Markers in the Diagnosis and Prediction of Autoimmune Type 1a Diabetes Clin. Diabetes, October 1, 2002; 20(4): 183 - 191. [Abstract] [Full Text] [PDF]

				M. R. Christie, J. Molvig, C. J. Hawkes, B. Carstensen, T. Mandrup-Poulsen, and the Canadian-European Randomised Control Trial Gro IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin Diabetes Care, July 1, 2002; 25(7): 1192 - 1197. [Abstract] [Full Text] [PDF]

				A. Imagawa, T. Hanafusa, J.-i. Miyagawa, Y. Matsuzawa, and The Osaka IDDM Study Group A Novel Subtype of Type 1 Diabetes Mellitus Characterized by a Rapid Onset and an Absence of Diabetes-Related Antibodies N. Engl. J. Med., February 3, 2000; 342(5): 301 - 307. [Abstract] [Full Text] [PDF]

				H. Borg, P. Fernlund, and G. Sundkvist Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus Clin. Chem., December 1, 1997; 43(12): 2358 - 2363. [Abstract] [Full Text] [PDF]

				H. Borg, P. Fernlund, and G. Sundkvist Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): two new 125I assays compared with [35S]GAD 65-ligand binding assay Clin. Chem., May 1, 1997; 43(5): 779 - 785. [Abstract] [Full Text] [PDF]